-
8/10/2019 sulfonacion en farmacologa y toxicologa 2 004.pdf
1/22
DRUG METABOLISM REVIEWS
Vol. 36, Nos. 3 & 4, pp. 823-843, 2004
Sulfonation in Pharmacology and Toxicology*
Frederick C. Kauffman
Laboratory for Cellular and Biochemical Toxicology, Ernest Mario School
of Pharmacy, Rutgers, The State University of New Jersey,
Piscataway, New Jersey, USA
ABSTRACT
Sulfonation has a major function in modulating the biological activities of a wide
number of endogenous and foreign chemicals, including: drugs, toxic chemicals,
hormones, and neurotransmitters. The activation as well as inactivation of many
xenobiotics and endogenous compounds occurs via sulfonation. The process is
catalyzed by members of the cytosolic sulfotransferase (SULT) superfamily consisting
of at least ten functional genes in hum ans. The reaction in intact cells may be reversed
by arylsulafatase present in the endoplasmic reticulum. Under physiological
conditions, sulfonation is regulated, in part, by the supply of the co-substrate/donor
mo lecule 3'-phosphadensoine-5-phosphosu lfate (PAPS ), and transport mech anisms by
which sulfonated conjugates enter and leave cells. Variation in the response of
individuals to certain drugs and toxic chemicals may be related to genetic
polymorphisms documented to occur in each of the above pathways. Sulfonation
has a major function in regulating the endocrine status of an individual by modulating
the receptor activity of estrogens and androgens, steroid biosynthesis, and the
metabolism of catecholamines and iodothyronines Sulfonation is a key reaction in the
body's defense against injurious chemicals and may have a major function during
early development since SULTs are highly expressed in the human fetus. As with
Supported in part by NIEHS Center Grant No. ES05052.
*Correspondence: Frederick C. Kauffman, Laboratory for Cellular and Biochemical Toxicology,
Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ
08854 , USA ; E-mail: kauffma@ rci.rutgers.edu.
-
8/10/2019 sulfonacion en farmacologa y toxicologa 2 004.pdf
2/22
82 4
KaufTman
many PhaseIand PhaseIIreactions, sulfonation may also serveasthe terminal stepin
activating certain dietary
and
environmental agents
to
very reactive toxic
intermediates implicated in carcinogenesis.
Key Words Sulfonation; Sulfation; Sulfotransferase; SULT; Sulfatase; PAPS.
INTRODUCTION
Sulfonation of low molecular weight compounds catalyzed by members of the
cytosolic sulfotransferase multigene family (SULT) is an important determinant of the
pharmacology and toxicology of a vast array of endogeneous and foreign chemicals
(Coughtrie, 2002; Strott, 2002). This pathway involves the transfer of a sulfonate group
(S0''~) from the universal donor 3'-phosphoadenosine 5'-phosphosulfate (PAPS) to an
appropriate substrate. Sulfonated conjugates are often incorrectly referred to as
sulfates because the transfer of an SO ~ group to a hydroxyl acceptor creates an
SO *ester. Various components of the sulfonation pathway are summarized in Fig. 1.
The sulfonation system resides primarily in cytosol but involves interaction with
The ulfonation ystem
A T P . S O ,
^PS Kinase
Sulfotransferase:SULT
-SO4
- ROSO3
Cytosol
Endoplasm ic Reticulum Sulfatase:ARSc
Figure 1 Scheme depicting interactions between various factors that influencethe netformation
and transportof sulfonate esters from intact cells. Availabilityof the obligatory cofactory, PAPS,is
present at relatively low concentrations and may limit the synthesis of sulfonate conjugates
catalyzedbyvarious SULTs. PAPSisformed via a single bifunctional enzyme that contains both
ATP sulfurylase
and
APS activities. Inorganic sulfate
and two
molecules
of
A TP
are
required
for
each molecule of PAPS syntheisized. Sulfonate ester formation may also be reversed via the
hydrolytic enzyme arylsulfatas-c presentin theendolplasmic reticulum. Sulfonate conjugates leave
-
8/10/2019 sulfonacion en farmacologa y toxicologa 2 004.pdf
3/22
Sulfonation in Pharm acology and Toxicology 8 5
arylsulfates-c (ARSc) in the endoplasmic reticulum and specific transport molecules
localized in the plasma membrane. Both organic acid transport molecules (OAT) (Buist
et al., 2003) and multidrug resistant proteins (mdrs) (Chu et al., 2004) have been
implicated in coupling sulfonate conjugate formation to transport from and into cells.
Sulfonate conjugates may also allosterically regulate mrp-mediated transport of other
conjugates such as glucuronides (Chu et al., 2004). PAPS is synthesized via ATP
sulfurylase and APS kinase which reside within a single bifunctional enzyme of
approximately 56 kDa (Lyle et al., 1994). Formation of sulfonated conjugates from
various substrates is catalyzed by cytosolic sulfotransferases (SULTs). Arylsulfatases
present in intact cells have the capacity to reverse the process of sulfonation in cells
and thus influence the process of net sulfonation (Coughtrie et al., 1998; Kauffman
et al., 1991; Tan and Pang, 2001). Under physiological conditions, each of these
components; availability of substrate and PAPS, as well as activities of both synthetic
SULTs and hydrolytic sulfatases, influence net availability of sulfonated conjugates.
The importance of sulfonation in modulating the function of many endogenous
compounds, including a large number of neurotransmitters and hormones as well as an
enormous number of xenobiotics in humans, is well established. Several excellent
reviews have appeared recently that consider progress made in understanding the
biological function of sulfonation and the regulation of expression of SULT isoforms in
specific tissues during critical periods of development (Coughtrie, 2002; Glatt et al.,
2001;
Strott, 2002). The object of this review is to highlight some important historical
aspects of the field and briefly review work on the sulfonation of xenobiotics and
endobiotics of particular interest to pharmacologists and toxicologists.
The process of sulfonation in biology was discovered in the late 19th century by
Eugen Baumann (1876), who isolated and characterized phenol sulfate from the urine
of a patient given phenol as an antiseptic. The enzymatic basis for the process was
discovered 80 years later when Lip ma nn's group discovered activ e sulfa te in their
pioneering studies on the metabolism of sulfanilamide (Robbins and Lippman, 1957).
This compound, which is the sulfuryl donor for most sulfonation reactions, is now
know to be 3-phosphoadenosyl- 5'-phosphosulfate (PAPS) (Klaassen and Bowles,
1997). Understanding the important role of sulfonation in the pharmacology and
toxicology of endogenous and foreign chemicals has advanced greatly since the
discovery of activ e sulfate, and in many ways has paralleled research with other
families of drug metabolizing enzymes including the cytochrome P450s and UDP
glucuronosyl transferases. Research underlying the great progress that has been made in
the past few years, due in large measure to the application of techniques in molecular
biology and modeling, is the subject of a number of recent reviews, (Coughtrie, 2002;
Weinshilboum et al., 1997). In light of Herbert Remmer's life time contributions to the
field of drug metabolism and his early work on both oxidative and conjugative
reactions (Bock et al., 1973; Remmer et al., 1975), he would be gratified by the
exciting work on sulfonation that has followed his pioneering studies.
Like many drug metabolizing enzymes, cytosolic SULTs compose a large
superfamily of genes. Full length cDNA for more than 50 mammalian and avian
-
8/10/2019 sulfonacion en farmacologa y toxicologa 2 004.pdf
4/22
8 6 KaufTman
sequences. SULTl and SULT2 families are the largest and are responsible for
sulfonating the greatest number of endogen ous and foreign, com pound s. There are
currently 11 known isoforms of human SULT enzymes representing the SULTl,
SULT2, and SULT4 families (Coughtrie, 2002). These are products of 10 genes, with
alternate splicing occurring with the first exon of the SULT2B1 gene as reviewed in
(Weinshilboum et al., 1997). The expression of SULTs is carefully regulated in terms
of tissue type, development, and hormonal regulation. Some of the properties of known
human SULT isoforms with regard to major sites of expression and specificities for
endogenous and xenobiotic substrates are summarized in recent reviews by Coughtrie
and his colleagues (Coughtrie, 2002; Coughtrie et al., 1998). Despite considerable
research, endobiotic and xenobiotic ligands for a number of SULT isoforms remain to
be identified. An interesting example here is the failure to identify substrates for a
highly conserved protein (SULT4A1) identified from the expressed sequence database
that appears to be expressed only in mammalian brain (Falany et al., 2000; Liyou et al.,
2003; Sakakibara et al., 2002). This protein is prominent in a number of brain
structures including the cerebral cortex, cerebellum, pituitary, and brainstem of rats and
humans; however to date, no endogenous nor xenobiotic substrate has yet been
identified for SULT4A1.
PHARMACOGENTICS
Inter-individual variation in expression of SULT isoforms that have pharmacolog-
ical and toxicological significance in humans are well established [for reviews see
(Coughtrie, 2002; Weinshilboum and Aksoy, 1994)]. Considerable information exists
concerning the molecular basis underlying variation in SULT activities, and a number
of molecular epidemiological studies linking SULT polymorphisms to disease
susceptibility have appeared (Bamber et al., 2001; Seth et al., 2000; Zheng et al.,
2001).
Pioneering studies carried out by Weinshilboum and his colleagues showed that
platelet phenol sulfotransferase activity and thermal stability were related to SULTIAl
genotype (H aenen et al., 19 91; Weinshilboum and Aksoy, 1994). The availability of a
simple colorimetric assay, and the presence of thermal stable and thermal labile forms
of phenol sulfotransferase in platelets, an easily accessible tissue, opened the possibility
of initiating studies into the heritability of biochemically distinct forms of SULT. Early
studies employing biochemical measurements showed that genetically determined
variation in the thermal stability of phenol sulfotransferase in platelets correlated with
individual differences in sulfonation of acetaminophen after oral administration (Reiter
and Weinshilboum, 1982). Using 4-nitrophenol as a substrate, Raftogianis et al. (1997)
observed m ore than a 50-fold variation in the activity of phenol sulfotransferase from
905 subjects. This enzyme, now known as SU L TI A l, is a broad spectru m
sulfotransferase involved in the metabolism and detoxification of many drugs and other
foreign chemicals as well as the bioactivation of many dietary and environmental
procarcinogens (Coughtrie and Johnston, 20 01 ; Glatt et al., 2000).
-
8/10/2019 sulfonacion en farmacologa y toxicologa 2 004.pdf
5/22
Sulfonation in Pharm acology and Toxicology 8 7
in the coding region of this enzyme in humans Cough trie, 2002; Weinshilboum and
Otterness, 1994). The two most common S UL TIA l alleles, termed SULT1A 1*1 and
SULT1A1*2, determined by gene sequencing studies involve a single amino acid
change at position 213. The allelic variant that possesses an arginine at position 213
SUL T1A 1*1) is more thermostabile than the variant containing histadine at this
position SU LT IA 1*2) when using p-nitrophenol as substrate. Pioneering work by
Weinshilboum and his colleagues showed that platelet enzyme activity and thermal
stability were related to SULTIAl genotype. Individuals with the SULTIAl*2
genotype had significantly lower platelet activity than 1A1*1/1A1*2 heterozygotes or
1A1*1 homozyg otes Raftogianis et al., 1997). The reduced activity noted in
SULTIAl*2 genotypes is likely due to alterations in amounts of expressed enzyme
since kinetic properties of recombinant SULTIAl isoforms failed to demonstrate
reduced activity of the 1A1*2 allozyme Li et al., 20 01 ; Tabrett and Coughtrie, 2003).
A reduced biological half-life due to enhanced proteosomal degradation has been
suggested as a possible mechanism accounting for low amounts of the SULTIAl*2
allozyme Coug htrie, 2002).
The occurrence of a common functional polymorphism in SU LT IA l has
stimulated a number of molecular epidemiological studies attempting to link individual
variation in SU LT IA l activity with certain pathologies notably breast Nowell et al.,
2002a; Saintot et al.,
2003;
Seth et al., 2000; Zheng et al., 2001), colon Bam ber et al.,
2001; Liang et al., 2003), prostate Nowell et al., 2004), and lung Liang et al., 2003)
cancers. Although these studies have produced confiicting results, they are valuable in
identifying associations that may occur between certain physiological factors, life
styles, and SULTIAl genotypes. For example, a significant increase in the frequency
of the wild type allele, SULTlAl*l, was noted in older individuals in a small
population-based study suggesting that the high sulfonation phenotype provided
protection against long term tissue damage arising from exposures to endogenous
chem icals or xenobiotcs with aging Cough trie et al., 1999). In contrast, several case
control studies concerning the onset of various cancers mentioned above suggest an
association between the high activity SULT1A]*1 allele and heightened risk of these
diseases in human populations. There is at least one study indicating that homozygosity
for the SU LT ]A 1*2 allele slightly reduced the risk for colorectal cancer Nowell
et al., 2002b).
A potential link between high activity and SULTIAl and increased risk from
certain dietary constituents has been suggested. A large number of environmental
mutagens and carcinogens, such as heterocyclic amines contained in well done meat,
are activated by sulfotransferases Glatt, 2000) . The risk of early-onset breast cancer as
well as the occurrence of other tumors may be increased in individuals having higher
amounts the SU LT IA l allele compared to controls Seth et al., 2000). Several studies
suggesting that variations in SU L TI A l alleles contribute to the risk of breast Zheng
et al., 2001) and prostate Now ell et al., 2004 ) cancer implied that risk to these cancers
was increased by the consumption of well done meats. Findings such as these, as well
as those of other studies, emphasize the importance of considering associations between
-
8/10/2019 sulfonacion en farmacologa y toxicologa 2 004.pdf
6/22
8 8 Kauffman
evidence is emerging that variation in these genes also contribute to pathophysiology in
humans. Sequencing of DNA samples for 60 African Americans and 60 Caucasian
Am erican subjects identified o ne non-synonymous SN P Lys234A rg) only in A frican
Am erican subjects Thom ae et al., 2003). Heterologous expression of this variant in
COS cells indicated decreased sulfonation of dopamine compared to wild type enzyme
expressed in the same system. A significant decrease in immunoreactive protein
compared to that of the wild type sequence was noted. Kinetic properties of the two
recombinant proteins did not differ. The authors provide data that this single amino
acid change leads to accelerated degradation through a proteosome-mediated process
Thomae et al., 2003).
Estrogen sulfotransferase SU L TI EI ) has the lowest Km values for estrogens of
the 11 known human SULT enzymes. A number of studies suggest that inter-individual
variation in the activity of this isoform is associated with the pathophysiology of
hormone-dependent diseases such as breast cancer. Using the same cohort of African
American and Caucasian Americans described above, Weinshilboum and his colleagues
identified three non-synonymous SNPs that were associated with altered levels of
expression and kinetic properties of sequences expressed heterologously in COS-1 cells
Adjei et al., 2003) . Such findings lend further crede nce to the idea that g enetically
determined variation in SULTIEI catalyzed sulfonation of estrogens contributes to the
pathophysiology of estrogen-dependent diseases as well as the biotransformation of
estrogens administered pharmacologically. Application of DNA sequencing and
analysis of the SULT2A1 gene and expression constructs derived from the same
cohort above identified three functional SNPs in DNA from African American subjects
Thomae et al., 2001). The most common of these non-synonymous SNPs occurred in
the dimerization motive Petrotchenko et al., 2001) that influenced the dimerization of
SULT2A1 in vitro.
PAPS is synthesized from ATP and inorganic sulfate by two isoforms of PAPS
synthetase PA PSSl and PAPSS 2) Besset et al., 2000; Xu et al., 2000 ). A rare
polymorphism GLU 532) in the PA PSSl identified in DNA from an African Am erican
subject was associated with a five-fold higher Km for inorganic sulfate compared to the
wild-typ e allozym e Xu et al., 2003). It is not known if this genetic variation in
PAPSSl is associated with decreased PAPS synthesis and altered sulfonate conjugation
in vivo.
SULFONATION OF ENDOGENOUS AND
FOREIGN CHEMICALS
Sulfotransferses from each of the major subfamilies of this group of enzymes are
involved in metabolism of broad classes of foreign and endogenous compounds. There
are several recent excellent reviews summarizing these reactions. An earlier review by
Miller and Surh 1994) summ arized the key function that sulfonation has in the
activation of a wide array of chemical carcinogens. There are also several recent
-
8/10/2019 sulfonacion en farmacologa y toxicologa 2 004.pdf
7/22
Sulfonation in Pharmacology and Toxicology
8 9
Table 1
Selected substrates for mam malian sulfotransferases.
Substrate SULT isoform Reference
Etidogettous chemicals
Catecholamines
Iodothyronines
Ascorbic acid
Vitamin D
Cholesterol
Estrogens
Dhydroepiandrosterone
Androgens
Neurosteroids
Bile acids
Xenobiotics
Drugs
Acetaminophen
Apomorphine
Butesonide
Ethinylestradiol
Minoxidil
Tamoxifen
Dietary constituents
Curcumin
Flavonoids
S U L T
lAl,
S U L T
1A3
SULTIAl
SULTIAl
SULT2A1
SULT2Blb
SULTIEI, lAl,1A 2
SULT2A1
SULTIAl
SULT2A1
SULT2A1
SULTIAl
SULTIAl,1A2,
1A3,lEl
SULT2A1
SULTIAl
SULTIAl,lCl
SULTIAl
SULTIAl,
IA3
SUL TIA l, 1A3,lCl
Buuetal.,1981;
Eisenhofer et al., 1999;
Taskinen et al.,
2003;
Thomae et al., 2003)
Kester et al.,
2003;
Li and Anderson, 1999;
Li et al., 2000; Rubin et al., 1999;
Visser, 1994; Visser et al., 1998)
Tolbert, 1985)
Axelson, 1985;
Echchgadda et al., 2004)
Strott and Higashi,
2003;
Yanai et al., 2004)
Adjei and Weinshilboum, 2002;
Mancini et al., 1992;
Purinton and Wood, 2000;
Qian et al., 2001)
Shimada et al., 2001;
Sugahara et al., 2003)
Chang et al., 2004)
Cascio et al., 2000;
Krueger and Papadopoulos, 1992;
Markowski et al., 2001)
Frye and Lacey, 1999;
Kitada et al.,
2003;
Palmer and Bolt, 1971;
Shen et al., 2000;
Song et al., 2001)
Reiter and Weinshilboum, 1982)
LeWitt, 2004;
Thomas and Coughtrie, 2003)
Meloche et al., 2002)
Chu et al., 2004)
Dooley, 1999;
Meisheri et al., 1993)
Chen et al, 2002;
Glatt et al., 1998)
Ireson et al., 2002)
Mesia-Vela and Kauffman,
2003;
Pai et al., 2001;
-
8/10/2019 sulfonacion en farmacologa y toxicologa 2 004.pdf
8/22
830 Kauffman
able 1 Continued.
Substrate
oxic chemicals
Pro carcinogens
Aliphatic and
benzylic alcohols
Alkenylbenzenes
Aromatic amines
and amides
Heterocyclic
aromatic amines
Polynuclear aromatic
hydrocarbons
Others
Perflorocarboxylic acids
Manganese
SULT isoform
SULT2A1
SULTIAl
SULTIAl, SULTIC
SULTIAl, 1A2, IA3
SULTI Al
SULTI Al
SULTI Al
Reference
(Miller and Surh, 1994)
(Duffel etal., 2001;
Glatt et al., 2000)
(Boberg et al., 1983)
(Glatt and Meinl, 2004;
King and Phillips, 1968;
Sakakibara et al., 1998)
(Buonarati et al., 1990;
Sugimura, 2002)
(Tiemersma et al., 2004;
Watabe etal., 1982)
(Witzmann et al., 1996)
(Ranasinghe et al., 2000)
b io t r a n s f o r ma t io n o f e n d o g e n e o u s c o mp o u n d s ( Co u g h t r i e , 2 0 0 2 ; S t r o t t , 2 0 0 2 ) .
Members of the SULT2A family a re pr imar i ly assoc ia ted with the metabol ism of
hydroxys te ro ids (Th om ae e t a l . , 20 01 ; W einsh i lbo um and Otte rness , 1994) . Se lec ted
examples of the function of sulfonation in the biotransformation of endogenous
com poun ds and xenobio t ics a re sum mar ized in Table 1 and brie fly d iscussed be low .
Endogenous Chemicals
Sulfonation has been recognized as a pathway for catecholamine inactivation in
man and an imals for at least 3 deca des (Buu et al., 1981 ; Roth and R ivett, 1982), and it
has been estimated that as much as 10% of the metabolism of dopamine and
norepinephrine in brain may be inactivated by this pathway (Rivett et al., 1982;
Whittemore and Roth, 1985). Most catechois studied are substrates for SULT isoforms
l A l , 1A2, 1A3, and l B l (Taskinen et al., 2003). A functional genetic polymorphysim
recently reported for human SULT 1A3 has been associated with accelerated
degradation via a proteosomal-mediated process (Thomae et al., 2003). Authors of
this report raised the possibility that such changes may be related to inherited
alterations in catecholamine sulfonation in humans. Dopamine sulfate exists at much
higher concentrations in human plasma than dopamine and appears to arise mainly
from dietary biogneic amines and sulfonation of dopamine produced in the myenteric
plexus of the gastroinitestinal tract via SULTl
A
which is expressed in large amounts
in the gastrointestinal tract (Eisenhofer et al., 1999). It has been suggested that more
than 75% of dopamine sulfate present in the body is produced via this pathway which
serves as a gu t-b loo d barrier for dietary biogenic amines and dopam ine produced in
-
8/10/2019 sulfonacion en farmacologa y toxicologa 2 004.pdf
9/22
Sulfonation in Pharm acology and Toxicology 83
have been linked to important developmental processes (Coughtrie, 2002). For ex-
ample, production of DHEA sulfate via SULT2A1 by the fetal adrenal is established as
a critical step in providing substrate for estrogen biosynthesis by the placenta during
pregnancy (Barker et al., 1994). Thyroid hormone bioavailability in the human fetus is
regulated, in part, by enzymatic deiodination and reversible sulfonation of
iodothyronines (Hume et al., 2001). Sulfonation of 3,3 -diiodothyronine was found to
correlate with SU LT IA l in a wide range of fetal tissues suggesting that this isoform is
primarily responsible for sulfonation of this hormone in fetal tissues (Richard et al.,
2001). SULTIAl may serve an important defense mechanism in the fetus since other
metabolic pathways are very low or absent in fetal tissues, and the human fetus
produces very high amounts of iodothyronine sulfates (Coughtrie, 2002).
Cholesterol sulfate and DHEA sulfate are the two most abundant sterol sulfonates
in the human circulation (Strott and Higashi, 2003). Their concentrations overlap and
range between 2 to 6 [xM in blood; how ever, w hile blood levels of cholesterol sulfate
remain relatively constant throughout life, levels of DHEA sulfate peak at puberty and
decline with age (Orentreich et al., 1984). Much is known about the physiological
function of the former in contrast to DHEA sulfate which, in large, remains a mystery.
In contrast, considerable information exists concerning the role of cholesterol sulfate as
a regulatory molecule in a variety of processes, e.g., keratinocyte differentiation,
epidermal and platelet cell adhesion, sperm capacitation, blood clotting, and fibrinolysis
(Strott and Higashi, 2003). Both compounds are sulfonated by members of the SULT2
family, which are primarily involved in the conjugation of neutral steroids and sterols.
DHEA is considered as the primary substrate for SULTIAl, which is also referred to
as DHE A sulfotransferase or hydroxysulfotransferase (Nagata and Yamaz oe, 2000 ).
SULT2B has been further divided into two isoforms derived from the same gene
(SULTIBI) differing in structure and substrate specificity; SULT2Bla and SULT2Blb
(Her et al., 1998). SULT2Blb acitively sulfonates cholesterol while SULT2Bla
sulfonates pregnenolone but not cholesterol (Fuda et al., 2002; Strott and Higashi,
2003). The recent finding that SULT2Blb is expressed in human platelets (Yanai et al.,
2004) enhances the opportunity to explore potential polymorphisms in this gene and
relationships to altered physiological processes regulated by cholesterol sulfate.
The term
neurosteroi s
designates steroids that are newly synthesized from
cholesterol or other precursors in the nervous system, and are still present in substantial
amounts after removal of peripheral steroidogenic organs (Mensah-Nyagan et al.,
1999). Initial steps in the synthesis of neurosteroids from cholesterol involves of
number of cytochrome P450s localized in brain (Hojo et al., 2004; Shibuya et al.,
2003). Sulfonation in brain is particularly important because a variety of neuro-
transmitter systems including GABA (Baulieu, 1998; Sullivan and Moenter, 2003),
cholinergic (Rhodes et al., 1997), glutaminergic (Flood et al., 1999) and a-opioid
(Monnet et al., 1995) receptors are modulated by both free and sulfonated neuro-
steroids, often in opposing ways. For example, pregnenolone is a barbiturate-like ago-
nist, whereas its sulfonated conjugates acts as a picrotoxin-like antagonist (Krueger and
Papadopoulos, 1992; Melchior and Allen, 1992). Dehydroepiandrosterone sulfate en-
hances acetylcholine release from the hippocampus while the unconjugated form does
-
8/10/2019 sulfonacion en farmacologa y toxicologa 2 004.pdf
10/22
-
8/10/2019 sulfonacion en farmacologa y toxicologa 2 004.pdf
11/22
Sulfonation in Pharmacology andToxicology 833
these inhibitors are polyphenols such as quereetin (Mesia-Vela and Kauffman, 2003;
Walle et al., 1995), ingredients in red wine (Jones et al., 1995), and tea and coffee
(Coughtrie et al., 1998). Tests with recombinant SULTl isofoms indicated that SULTs
lA l, 1A2, and 1A3 are inhibited to varying degrees by a wide range of dietary
polyphenols; however, the most potent inhibitors found in this class of chemicals were
epicatechin gallate, epigallocatechin, and gallocatechin gallate (Coughtrie and Johnston,
2001). Further kinetic experiments in this same study indicated that inhibitory potency
toward each of the three isoforms varied considerably with SULTIAl being the most
sensitive. Ki values for epicatechin gallate and epigallocatechin gallate were 64 nm and
42 nm, respectively. Further studies to determine the possibility that compounds such
as the gallates in tea and coffee modulate variants of SULTIAl in human subjects in
vivo and the consequences of such effects would be valuable.
Toxic hemicals
It is well established that sulfotransferases bioactivate a host of chemicals, many of
which are dietary constituents, to reactive intermediates that are implicated in
carcinogenesis. Much of our understanding of the involvement of reactive sulfuric acid
esters in chemical carcinogenesis stems from the pioneering work of James and
Elizabeth Miller (Miller, 1970). Examples of chemicals that are converted to DNA- and
protein adducting species by sulfonation include benzylic alcohols of polycyclic
aromatic hydrocarbons (PAHs), estragole, safrole, as well as various hydoroxyaryl-
amines, arylhydroxamic acids formed from heterocyclic amines found in cooked meat
and fish (Miller and Surh, 1994). A principle pathway for chemical carcinogenesis is
the formation of toxic and very reactive sulfuric acid esters that undergo heterocyclic
cleavage to generate sulfate ions and potent electrophiles that combine.avidly with
nucleophilic groups in cellular DNA and proteins. Much recent work in toxicology has
been devoted to defining the activation of various pro-carcinogens by specific SULT
isoforms (Glatt and Meinl, 2004; Glatt et al., 1995; Sakakibara et al., 1998). A recent
study of nitrofen, that had been used as a herbicide in Germany until its carcinogenic
and teratogenic activities were detected in rodents, illustrates the principle of using
genetically manipulated strains of
almonella typhimuium
to evaluate the role of
specific SULT isoforms in mutagenagenesis (Glatt and Meinl, 2004).
Further appreciation for the importance of sulfonation in toxicology comes from
the finding that a number of hydroxylated metabolites of polychlorinated biphenyls are
extremely potent inhibitors of SU LT IE I with Ki s in the picomolar range (K ester et al.,
2000 ). Since SU LT IEI is the primary enzyme responsible for inactivation of estrogens
in humans, the authors suggest that the endocrine disrupting effects of these ubiquitous
environmental pollutants occur via the high capacity of their hydroxylated metabolites
to inhibit estrogen sulfonation via SULTIAl.
FUTURE DIRE TIONS
-
8/10/2019 sulfonacion en farmacologa y toxicologa 2 004.pdf
12/22
8 4 Kauffman
function during fetal and early postnatal life including biotransformation of many
endogenous and foreign chemicals. It will be important to gain further understanding of
mechanisms regulating the expression of various elements of the sulfonation system and
the physiological consequences of alterations in this system during early life.
Evidence collected over the last decade suggest that sulfonation is critical to
regulating the actions of steroids within the central nervous system. Important questions
concerning mechanisms regulating the expression of various elements of the sulfonation
system in brain and other tissues remain to be answered. Some elements involved in
regulating expression of cytochrome P450 enzymes may also function in transcrip-
tionally inducing cytosolic sulfotranferases. For example, the vitamin D receptor
mediating nuclear signaling, known to induce cytochrome P450 expression also appears
to be involved along with the farnesoid X nuclear receptor in stimulating endogenous
SULT2A 1 expression Echchgadda et al., 2004; Song et al., 2001). Progress is being
made in understanding the regulation of this isofrom e.g., Runge-M orris et al., 1999);
however there is little known concerning mechanisms regulating the expression of other
SULT isoforms.
Finally, progress in understanding interactions between the different components of
the sulfonation system in various organs and tissues is emerging. Recent work
employing mRNA expression and immunohistochemistry has localized steroid sulfatase
and various organic acid transport proteins in biopsy samples of human temporal lobe
Steckelbroeck et al., 2004). It is tempting to speculate that these components function
together with de novo biosynthesis of DHEA-sulfonate and other 3-3-hydroxy steroids
to regulate levels of these steroids at critical sites in the brain.
R F R N S
Adjei, A. A., Weinshilboum, R. M. 2002). Catecholestrogen sulfation; p ossible role in
carcinogenesis. Biochem. Biophys. Res. Commun. 292;402-408.
Adjei, A. A., Thomae, B. A., Prondzinski, J. L., Eckloff B. W., Wieben, E. D.,
Weinshilboum, R. M. 2003). Human estrogen sulfotransferase SU LT IE I)
pharmacogenomics; gene resequencing and functional genomics.
Br. J. Pharmacol.
139;1373-1382.
Aldred, S., Wa ring, R. H. 1999). Localisation of dehydroepiandrosterone sulphotrans-
ferase in adult rat brain. Brain Res. Bull. 48;291-296. [In Process Citation].
Axelson, M. 1985). 25-Hydroxyvitamin D3 3-sulphate is a major circulating form of
vitamin D in man. FEBS Lett.
191;
171-175.
Bam ber, D. E., Fryer, A. A., Strange, R. C , Elder, J. B., Deakin, M., Rajagopal, R.,
Fawo le, A., Gilissen, R. A., Cam pbell, F. C , Coughtrie, M. W . 2001). Phenol
sulphotransferase SULT1A1*1 genotype is associated with reduced risk of
colorectal cancer.
Pharmacogenetics
l l ; 6 7 9 - 6 8 5 .
Barker, E. V., Hum e, R., Hallas, A., Coug htrie, M. W. H. 1994). D ehydroepiandroste-
rone sulfotransferase in the developing human fetus; quantitative biochemical
-
8/10/2019 sulfonacion en farmacologa y toxicologa 2 004.pdf
13/22
Sulfonation in Pharm acology and Toxicology 8 5
Baumatin, E. (1876). Ueber sulfosauren im harn.
Ber. Dtsch. Chem.
5 4 - 5 8 .
Besset, S., Vincourt, J. B., Am alric, F., Girard, J. P. (2000). Nuclear localization of PAPS
synthetase 1: a sulfate activation pathway in the nucleus of eukaryotic cells.FASEB
J.
14:345-354.
Boberg, E . W., Miller, E. C , Miller, J. A., Poland, A., Liem, A . (1983). Strong
evidence from studies with brachymorphic mice and pentachlorophenol that
r-sulfooxysafro le is the major ultimate electrophilic and carcinogenic m etabolite of
l -hydroxysafrole in m ouse liver. Cancer Res.43 :5163-5173.
Bock, K. W., Frohling, W., Remmer, H., Rexer, B. (1973). Effects of phenobarbital and
3-methylcholanthrene on substrate specificity of rat liver microsomal UDP-
glucuronyltransferase.
Biochim. Biophys. Acta
327:46-56 .
Buist, S. C , Cherrington, N . J., Klaassen, C. D. (2003). Endocrine regulation of rat
organic anion transporters. Drug Metab. Dispos. 31 :559-564.
Buon arati, M. H., Turteltaub, K. W ., Shen, N. H., Felton, J. S. (1990). Role of sulfation and
acetylation in the activation of 2-hydroxyamino-l-methyl-6-phenylimidazo[4,5-
b]pyridine to intermediates which bind DNA. Mutat. Res. 245:185-190.
Buu, N. T., Duh aime, J., Savard, C , Truong , L., Kuchel, O. (1981). Presence of
conjugated catecholamines in rat brain: a new method of analysis of catecholamine
sulfates. J. Neuwchem. 36 :769-772.
Cascio, C , Guarne ri, R., Russo, D., De Leo , G., Guarne ri, M., Piccoli, F., Guarneri, P.
(2000). Pregnenolone sulfate, a naturally occurring excitotoxin involved in delayed
retinal cell death.
J. Neurochem.
74 :2380-2391.
Chang, H. J., Shi, R., Rehse, P., Lin, S. X. (2004). Identifying androsterone (ADT) as a
cognate substrate for human dehydroepiandrosterone sulfotransferase (DHEA-ST)
important for steroid homeostasis: structure of the enzyme-ADT complex.
J. Biol.
Chem. 279:2689-2696.
Chen, G., Yin, S., Ma iti, S., Shao, X. (2002). 4-Hydroxytamoxifen sulfation metabo lism.
J. Biochem. Mol. Toxicol.
16:279-285.
Chu, X. Y., Huskey, S. E. W., Braun, M. P., Sarkadi, B., Evans, D. C , Evers, R. (2004).
Transport of ethinylestradiol glucuronide and ethinylestradiol sulfate by the
multidrug resistance proteins MRPl, MRP2, and MRP3.
J. Pharmacol. Exp. Ther.
309:156-164.
Coughtrie, M. W. (2002). Sulfation through the looking glassrecent advances in
sulfotransferase research for the curious.
Pharmacogenomics J.
2 :297-308.
Coughtrie, M. W., Johnston, L. E. (2001). Interactions between dietary chemicals and
human sulfotransferasesmolecular mechanisms and clinical significance.
Drug
Metab. Dispos. 29 :522-528.
Coughtrie, M. W., Sharp, S., Maxwell, K., Innes, N. P. (1998). Biology and function of
the reversible sulfation pathway catalysed by human sulfotransferases and
sulfatases. Chem. Biol. Interact. 109:3-27 .
Coug htrie, M. W., Gilissen, R. A., Shek, B., Strange, R. C , Fryer, A. A., Jones, P. W.,
Bamber, D. E. (1999). Phenol sulphotransferase S U LT lA l polymorphism:
molecular diagnosis and allele frequencies in Caucasian and African populations.
-
8/10/2019 sulfonacion en farmacologa y toxicologa 2 004.pdf
14/22
-
8/10/2019 sulfonacion en farmacologa y toxicologa 2 004.pdf
15/22
Sulfonation in Pharm acology and Toxicology 8 7
Hely, M. A ., Fung, V. S. C. (2000). Treatment of Parkinso n s disease.J Clin N eurosci
7:484-494.
Her, C , Wood , T. C , Eichler, E. E., Mo hrenweiser, H. W., Ram agli, L. S., Siciliano,
M. J., We inshilboum, R. M. (1998). Human hydroxy steroid sulfotransferase
SULT2B1:
two enzymes encoded by a single chromosome 19 gene.
Genomics
53:284-295 .
Hojo,
Y., Hattori, T. A., Enami, T., Furukawa, A., Suzuki, K., Ishii, H. T., Mukai, H.,
Morrison, J. H., Janssen, W. G., Kominami, S., Harada, N., Kimoto, T., Kawato, S.
(2004). Adult male rat hippocampus synthesizes estradiol from pregnenolone by
cytochromes P45017alpha and P450 aromatase localized in neurons.
Proc Nail
cad
Sci U S A
101:865-870.
Hum e, R., Richard, K., Kaptein, E., Stanley, E. L., Visser, T. J., Coug htrie, M. W. (2001 ).
Thyroid hormone metabolism and the developing human lung.
Biol Neona te
80
(Suppl. 1 ) :18-21 .
Ireson, C. R., Jones, D. J. L., Orr, S., Coughtrie, M. W. H., Boocock, D. J., Williams,
M. L., Farmer, P. B., Steward, W. P., Gescher, A. J. (2002). Metabolism of the
cancer chemopreventive agent curcumin in human and rat intestine. Cancer
Epidemiol Biomark Prev
11:1 5- 1 1 1 .
Jones, A. L., Roberts, R. C , Colvin, D. W., Rubin, G. L., Coughtrie, M. W.
(1995). Reduced platelet phenolsulphotransferase activity towards dopamine and
5-hydroxytryptamine in migraine.
Eur J Clin Pharmacol
49:109-114.
Jonsson, G., Astrom, A., Andersson, P. (1995). Budesonide is metabolized by
cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos
23:137-142.
Kalsi, J., Kell, P. (2004). Update on oral treatments for male erectile dysfunction.
J Eur
cad Dermatol Venereol 18:267-274.
Kauffman, F. C , Wh ittaker, M., Anundi, L, Thurm an, R. G. (1991). Futile cycling of a
sulfate conjugate by isolated hepatocytes. Mol Pharmacol 39:414-420.
Kester, M. H., Bulduk, S., Tibboel, D., Meinl, W., Glatt, H., Falany, C. N., Coughtrie,
M. W ., Bergman, A., Safe, S. H., Kuiper, G. G., Schuur, A. G., Brouwer, A ., Visser,
T. J. (2000). Potent inhibition of estrogen sulfotransferase by hydroxylated
PCB metabolites: a novel pathway explaining the estrogenic activity of PCBs.
Endocrinology
141:1897-1900.
Kester, M. H., Kaptein, E., van Dijk, C. H., Roest, T. J., Tibboel, D., Coughtrie, M. W.,
Visser, T. J. (2002). Characterization of iodothyronine sulfatase activities in hum an
and rat liver and placenta.
Endocrinology
143:814-819.
Kester, M. H. A., Kaptein, E., Roest, T. J., van Dijk, C. H., Tibboel, D., Meinl, W.,
Glatt, H., Coughtrie, M. W. H., Visser, T. J. (2003). Characterization of rat
iodothyronine sulfotransferases.
Am J Physiol Endocr Metab
285 :E592-
E598.
King, C. M ., Phillips,
B .
(1968). Enzyme-catalyzed reactions of the carcinogen N -hydroxy-
2-fluorenylacetamide with nucleic acid.
Science
159:1351-1353.
Kitada, H., Miyata, M., Nakamura, T., Tozawa, A., Honma, W., Shimada, M., Nagata,
-
8/10/2019 sulfonacion en farmacologa y toxicologa 2 004.pdf
16/22
838 KaufTman
Klaassen, C. D ., Bowles, J. W. (1997). The im portance of 3 -phophoaden osine
5 -phosphosulfate (PAPS) in the regulation of sulfation.
FASEB J
11:404-418.
Krueger, K. E., Papadopoulos, V. (1992). Mitochondrial benzodiazapines receptors
and the regulation of steroid biosynthesis.
Annu Rev Pharmacol Toxicol
32 :211 -
237.
LeWitt, P. A. (2004). Subcutaneously administered apomorphine: pharmacokinetics and
metabolism.
Neurology
62 :S 8-S 11 .
Li, X., Anderson, R. J. (1999). Sulfation of iodothyronines by recombinant human liver
steroid sulfotransferases.
Biochem Biophys Res Commun
263:632-639.
Li,
X., Clemens, D. L., Anderson, R. J. (2000). Sulfation of iodothyronines by human
sulfotransferase lCl (SULTICI)*. Biochem Pharmacol 60:1713-1716.
Li,
X., Clemens, D. L., Cole, J. R., Anderson, R. J. (2001). Characterization of human
liver thermostable phenol sulfotransferase (S U L TI A l) allozym es with 3,3 ,5 tri
iodothyronine as the substrate. J Endocrinol 171:525-532.
Liang, G., Miao, X., Zhou, Y., Tan, W., Lin, D. (2003). A functional polymorphism in the
SULTIAl gene (G638A) is associated with risk of lung cancer in relation to
tobacco smoking. Carcinogenesis 63:3987-3990.
Liyou, N. E., Buller, K. M., Tresillian, M. J., Elvin, C. M., Scott, H. L., Dodd, P. R.,
Tannen berg, A. E., McM anus, M. E. (2003). Localization of a brain sulfotransfer-
ase, SULT4A1, in the human and rat brain: an immunohistochemical study.
J Histochem Cytochem 51:1655-1664.
Lyle,
S., Stanczak, J., Ng, K., Schwartz, N. B. (1994). Rat chondrosarcoma ATP
sulfurylase and adenosine 5 -phosphosulfate kinase reside on a single bifunctional
protein. Biochemistry 33:5920-5925.
Mancini, M. A., Song, C. S., Rao, T. R., Chatterjee, B., Roy, A. K. (1992). Spatio-
temporal expression of estrogen sulfotransferase within the hepatic lobule of male
rats:
implication of in situ estrogen inactivation in androgen action.
Endocrinology
131:1541-1546.
Markowski, M., Ungeheuer, M., Bitran, D., Locurto, C. (2001). Memory-enhancing
effects of DHEAS in aged mice on a win-shift water escape task. Physiol Behav
72:521-525 .
Meisheri, K. D., Garland, M., Johnson, A., Puddinoton, L. (1993). Enzymatic and non-
enzymatic sulfation mechanisms in the biological actions of minoxidil. Biochem
Pharmacol 45:271-279.
Melchior, C. L., Allen, P. M. (1992). Interaction of pregnanolone and pregnenolone
sulfate with ethanol and pentobarbital.
Pharmacol Biochem Behav
42 :605-611 .
Meloche, C. A., Sharma, V., Swedmark, S., Andersson, P., Falany, C. N. (2002).
Sulfation of budesonide by human cytosolic sulfotransferase, dehydroepiand roster-
one-sulfotransferase (DHEA-ST). Drug Metab Dispos 30:582-585.
Mensah-N yagan, A. G., Do-R ego, J. L., Beaujean, D., Luu-T he, V., Pelletier, G., Vaudry,
H. (1999). Neurosteroids: expression of steroidogenic enzymes and regulation of
steroid biosynthesis in the central nervous system.
Pharmacol Rev 51 :63 - 81 .
Mesia-Vela, S., Kauffman, F. C. (2003). Inhibition of rat liver sulfotransferases
-
8/10/2019 sulfonacion en farmacologa y toxicologa 2 004.pdf
17/22
Sulfonation in Pharm acology and Toxicology 8 9
Possible role of metabotropic sigmal-like receptors.
J. Biol. Chem.
277:28725-
28732.
Migues, P. V., Johnston, A. N., Rose, S. P. (2002). Dehydroepiandosterone and its
sulphate enhance memory retention in day-old chicks.N euroscience 109:243-251.
Miller, J. A. (1970). Carcinogenesis by chemicals: an overview.
Cancer Res.
30 :559-
576.
Miller, J. A., Surh, Y.-J. (1994). Sulfonation in chemical carcinogenesis. In: Kauffman, F.
C , ed.
Conjugation Deco njugation Reactions in Drug Me tabolism and To xicity.
New York: Springer-Verlag, pp. 429-457.
Monnet, F. P., Mahe, V., Robel, P., Baulieu, E. E. (1995). Neurosteroids, via sigma
receptors, modulate the [3H]norepinephrine release evoked by N-methyl-D-
aspartate in the rat hippocampus.
Proc. Natl.
Acad
Sci. U. S. A.
92 :3774-3778.
Mulder, G. J., Jakoby, W. B. (1990). Sulfation. In: Mulder, G. J., ed. Conjugation
Reactions in Drug Metabolism. New York: Taylor and Francis, pp. 107-161 .
Nagata, K., Yamazoe, Y. (2000). Pharmacogenetics of sulfotransferase. Annu. Rev.
Pharmacol. Toxicol.
40 :159-176.
Nagata, K., Ozawa, S., Miyata, M., Shimada, M., Gong, D. W., Yamazoe, Y., Kato, R.
(1993). Isolation and expression of a cDNA encoding a male-specific rat
sulfotransferase that catalyzes activation of N-hydroxy-2-acetylaminofluorene.
J. Biol. Chem.
268:24720-24725.
Now ell, S., Sweeney, C , W inters, M., Stone, A., Lang, N . P., Hutchins, L. F., Kadlubar,
F.
F., Am brosone, C. B. (2002). Association between sulfotransferase lA l geno-
type and survival of breast cancer patients receiving tamoxifen therapy. J. Natl.
Cancer Inst. 94:1635-1640.
Now ell, S., Coles, B., Sinha, R., MacL eod, S., Luke Ratnasinghe, D ., Stotts, C ,
Kadlubar, F. F., Ambrosone, C. B., Lang, N. P. (2002). Analysis of total meat
intake and exposure to individual heterocyclic amines in a case-control study of
colorectal cancer: contribution of metabolic variation to risk.
Mutat. Res. Fundam.
Mol Mech. Mutagen.
506-507:175-185.
Nowell, S., Ratnasinghe, D. L., Ambrosone, C. B., Williams, S., Teague-Ross, T.,
Trimble, L., Runnels, G., Carrol, A., Green, B., Stone, A., Johnson, D., Greene, G.,
Kadlubar, F. F., Lang, N. P. (2004). Association of SU LT lA l phenotype and
genotype with prostate cancer risk in African-Americans and Caucasians. Cancer
Epidemiol. Biomark. Prev. 13:270-276.
O Co nnell, E. J. (2003). Review of the unique properties of budesonide.
Clin. Ther.
25
(Suppl C):C42-C60.
Orentreich, N., Brind, J. L., Rizer, R. L., Vogelman, J. H. (1984). Age changes and sex
differences in serum dehydroepiandrosterone sulfate concentrations throughout
adulthood. J. Clin. Endocrinol. Metab. 59 :551-555.
Pai, T. G., Suiko, M., Sakakibara, Y ., Liu, M. C. (2001). Sulfation of flavonoids and other
phenolic dietary compounds by the human cytosolic sulfotransferases.
Biochem.
Biophys. Res. Commun.
285:1175-1179.
Palmer, R. H., Bolt, M. G. (1971). Bile acid sulfates. I. Synthesis of lithocholic acid
-
8/10/2019 sulfonacion en farmacologa y toxicologa 2 004.pdf
18/22
84 Kauffman
Petrotchenko, E. V., Pedersen, L. C , Borchers, C. H., Tomer, K. B., Negishi, M. 2001).
The dimerization motif of cytosolic sulfotransferases.
FEBS Lett.
490 :39 -43 .
Purinton, S. C , Wo od, C. E. 2000). Ovine fetal estrogen sulfotransferase in brain regions
important for hypothalamus-pituitary-adrenal axis control.
Neuroendocrinology
71:237-242.
Qian, Y. M., Sun, X. J., Tong, M . H., Li, X. P., Richa, J., Song, W. C. 2001). Targeted
disruption of the mouse estrogen sulfotransferase gene reveals a role of estrogen
metabolism in intracrine and paracrine estrogen regulation. Endocrinology
142:5342-5350.
Raftogianis, R. B ., Wood, T. C , Otterness, D. M., Van Loon, J. A., W einshilboum, R. M.
1997). Phenol sulfotransferase pharmacogenetics in humans: association of
common SULTIAl alleles with TS PST phenotype*L
Biochem. Biophys. Res.
Commun.
239:298-304.
Ranasinghe, J. G., Liu, M. C , Sakakibara, Y., Suiko, M. 2000). M anganese
administration induces the increased production of dopamine sulfate and depletion
of dopamine in Sprague-Dawley rats. J. Biochem . Tokyo) 128:477-480.
Reiter, C , We inshilboum, R. 1982). Platelet phenol sulfotransferase activity: correlation
with sulfate conjugation of acetaminophen.
Clin. Pharmacol. Ther.
32 :612-621 .
Remm er, H., Bock, K. W., Rexer, B. 1975). Relationship between microsomal
hydroxylase and glucuronyltransferase.
Adv. Exp. Med. Biol.
58 :335-341 .
Rhode s, M. E., Li, P. K., Flood, J. F., Johnson, D. A. 1996). Enhancem ent of
hippocampal acetylcholine release by the neurosteroid dehydroepiandrosterone
sulfate: an in vivo microdialysis study. Brain Res. 733:284-286.
Rhode s, M. E., Li, P.-K., Burke, A. M., Johnson, D. A. 1997). Enhanced plasma
DHEAS,
brain acetylcholine and memory mediated by steroid sulfatase inhibition.
Brain Res.
773:28-32 .
Richard, K., Hume, R., Kaptein, E., Stanley, E. L., Visser, T. J., Coughtrie, M. W . 2001).
Sulfation of thyroid hormone and dopamine during human development: ontogeny
of phenol sulfotransferases and arylsulfatase in liver, lung, and brain.
J. Clin.
Endocrinol. Metab.
86:2734-2742.
Rivett, A. J., Eddy , B. J., Roth, J. A. 1982 ). Con tribution of sulfate conjugation,
deamination, and O-methylation to metabolism of dopamine and norepinephrine in
human brain.
J. Neurochem.
39:1009-1016.
Rob bins, P. W., Lippman, F. 1957 ). Isolation and identification of active sulfate.
J. Biol.
Chem.229:837-851.
Roth, J. A., Rivett, A. J. 1982). Does sulfate conjugation contribu te to the metabolic
inactivation of catecholamines in humans? Biochem. Pharmacol. 31:3017-3021.
Rubin, G. L., Harrold, A. J., Mills, J. A., Falany, C. N. 1999). Regulation of
sulphotransferase expression in the endometrium during the menstrual cycle,
by oral contraceptives and during early pregnancy. Mol. urrtan
Reprod
5 :995-
1002.
Rung e-M orris, M., Wu, W., Kocarek, T. A. 1999 ). Regu lation of rat hepatic
hydroxysteroid sulfotransferase SUL T2-40/41) gene expression by glucocorti-
-
8/10/2019 sulfonacion en farmacologa y toxicologa 2 004.pdf
19/22
Sulfonation in Pharm acology and Toxicology 84
catechol-o-methyltransferase and tobacco exposure in breast cancer risk. Int J
Cancer
107:652-657.
Sakakibara, Y., Yanagisawa, K., Katafuchi, J., Ringer, D. P., Takami, Y., Nakayama, T.,
Suiko, M., Liu, M. C. (1998). Molecular cloning, expression, and characterization
of novel human SULTIC sulfotransferases that catalyze the sulfonation of N-
hydroxy-2- acetylaminofluorene.
J B iol Chem
273:33929-33935.
Sakakibara, Y., Suiko, M., Pai, T. G., Nakayama, T., Takami, Y., Katafuchi, J., Liu, M.
C. (2002). Highly conserved mouse and human brain sulfotransferases: molecular
cloning, expression, and functional characterization.
Gene
285:39-47 .
Seth, P., Lunetta, K. L., Bell, D. W., Gray, H., Nasser, S. M., Rhei, E., Kaelin, C. M.,
Iglehart, D. J., Marks, J. R., Garber, J. E., Haber, D. A., Polyak, K. (2000). Phenol
sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast
cancer.
Cancer Res
60:6859-6863.
Shen, W., Mennerick, S., Covey, D. F., Zorumski, C. E. (2000). Pregnenolone sulfate
modulates inhibitory synaptic transmission by enhancing GABA(A) receptor
desensitization. J Neurosci 20:3571-3579.
Shibuya, K., Takata, N., Hojo, Y., Eurukawa, A., Yasumatsu, N., Kimoto, T., Enami, T.,
Suzuki, K., Tanabe, N., Ishii, H., Mukai, H., Takahashi, T., Hattori, T. A., Kawato,
S. (2003). Hippocampal cytochrome P450s synthesize brain neurosteroids which
are paracrine neuromodulators of synaptic signal transduction. Biochim Biophys
Acta
1619:301-316.
Shimada, M., Yoshinari, K., Tanabe, E., Shimakawa, E., Kobashi, M., Nagata, K.,
Yamazoe, Y. (2001). Identification of ST2A1 as a rat brain neurosteroid
sulfotransferase mRNA. Brain Res 920:222-225.
Song, C. S., Echchgadd a, L, Baek, B. S., Ahn, S. C , Oh, T., Roy, A. K., Chatterjee, B .
(2001). Dehydroepiandrosterone sulfotransferase gene induction by bile acid
activated farnesoid X receptor. J Biol C hem 276:42549-42556.
Steckelbroeck, S., Nassen, A., Ugele, B., Ludwig, M., Watzka, M., Reissinger, A.,
Clusmann, H., Lutjohann, D., Siekmann, L., Klingmuller, D., Hans, V. H. (2004).
Steroid sulfatase (STS) expression in the human temporal lobe: enzyme activity,
mRNA expression and immunohistochemistry study.
J Neurochem
89:403-417.
Strott, C. A. (2002). Sulfonation and molecular action.
Endocr Rev
23:703-732.
Strott, C. A., H igashi, Y. (2003). Cholesterol sulfate in human p hysiology: w hat s it all
about? J Lipid Res 44:1268-1278.
Sugahara, T., Y ang, Y. S., Liu, C. C , Pai, T. G., Liu, M. C. (2003). Sulphonation of
dehydroepiandrosterone and neurosteroids: molecular cloning, expression, and
functional characterization of a novel zebrafish SULT2 cytosolic sulphotransferase.
Biochem J 375:785-791.
Sugimura, T. (2002). Eood and cancer. Toxicology 181 -182 :17 -2L
Sullivan, S. D., Moenter, S. M. (2003). Neurosteroids alter gamma-aminobutyric acid
postsynaptic currents in gonadotropin-releasing hormone neurons: a possible
mechanism for direct steroidal control.
Endocrinology
144:4366-4375.
Tabrett, C. A., Coug htrie, M. W. H. (2003). Phenol sulfotransferase lA l activity in
-
8/10/2019 sulfonacion en farmacologa y toxicologa 2 004.pdf
20/22
84 Kauffman
and estrone sulfate in enriched periportal and perivenous rat hepatocytes.
Drug
Metab. Dispos.
29 :335-346.
Taskinen, J., Ethell, B. T., Pihlavisto, P., Hood, A. M., Burchell, B., Coughtrie, M. W.
(2003).
Conjugation of catechols by recombinant human sulfotransferases, UDP-
glucuronosyltransferases, and soluble catechol 0-methyltransferase: structure-
conjugation relationships and predictive models. Drug Metab. Dispos. 31 :1187-
1197.
Thomae, B. A., Eckloff B., Ereimuth, R. R., Carlini, E., Wieben, E., Weinshilboum,
R. M. (2001). Human sulfotransferase (SULT) 2A1 pharmacogenetics: genotype
to phenotype studies.
Clin. Pharmacol. Ther.
69:94.
Thomae, B. A., Rifki, O. E., Theobald, M. A., Eckloff B. W., Wieben, E. D.,
Weinshilboum, R. M. (2003). Human catecholamine sulfotransferase (SULT
A3)
pharmacogenetics: functional genetic polymorphism. J. Neurochem. 87 :809-819.
Thomas, N. L., Coughtrie, M. W. (2003). Sulfation of apomorphine by human
sulfotransferases: evidence of a major role for the polymorphic phenol
sulfotransferase, SULTlAl.
Xenobiotica
33:1139-1148.
Tiemersma, E. W., Bunschoten, A., Kok, E. J., Glatt, H., de Boer, S. Y., Kampman, E.
(2004).
Effect of SULTlAl and NAT2 genetic polymorphism on the associa-
tion between cigarette smoking and colorectal adenomas.
Int. J. Cancer
108:97-
103.
Tolbert, B. M. (1985 ). Metabolism and function of ascorbic acid and its metabolites.
Int.
J. Vitam. Nutr Res. Suppl.
27 :121-138.
Visser, T. J. (1994). Role of sulfation in thyroid hormone metabolism. Chem. Biol.
Interact.
92 :293-303.
Visser, T. J., Kaptein, E., Glatt, H., Bartsch, L, Hagen, M., Coughtrie, M. W. (1998).
Characterization of thyroid hormone sulfotransferases. Chem . Biol. Interact.
109:279-291.
Wa lle, T., Eaton, E. A., Walle, U. K. (199 5). Quercetin, a potent and specific inhibitor of
the human P-form phenolsulfotransferase.
Biochem. Pharmacol.
50 :731-734.
Watabe, T., Ishizuka, T., Isobe, M., Ozawa, N. (1982). A 7-hydroxymethyl sulfate ester
as an active metabolite of 7,12- dimethylbenz[alpha]anthracene. Science 215 :403-
405.
Weinshilboum, R., Aksoy, I. (1994). Sulfation pharmacogenetics in humans.Chem. Biol.
Interact.
92 :233-246.
We inshilboum, R., Otterness, D. (1994). Sulfotransferase enzym es. In: Kauffman, E. C ,
ed . Conjugation Decon jugation Reactions in Drug Metabolism and Toxicity.
Berlin: Springer-Verlag, pp. 45-78.
We inshilboum, R . M., Otterness, D. M., Aksoy, I. A., Wood, T. C , Her, C , Raftogianis,
B. B. (1997). Sulfotransferase molecular biology: cDNAs and genes. FASEB J.
11:3-14.
Whittemore, R. M., Roth, J. A. (1985). Effect of phosphatase inhibition of in vitro
dopam ine sulfation and 3 -phosphoad enosine-5 -phosphosulfate catabolism in
human brain.
Biochem. Pharmacol.
34:3853-3856.
-
8/10/2019 sulfonacion en farmacologa y toxicologa 2 004.pdf
21/22
Sulfonation in Pharmacology and Toxicology 84
Moon, E., Kim, U. J., Xu, J. P., Siciliano, M. J., Weinshilboum, R. M. (2000).
Human 3 -phosphoadenosine 5 -phosphosulfate synthetase 1 (PA PSS l) and
PAPSS2: gene cloning, characterization and chromosomal localization. Biochem
Biophys Res Commun
268:437-444.
Xu, Z. H., Thomae, B. A.,Eckloff B. W., Wieben, E. D ., Weinshilboum, R. M . (2003).
Pharm acogenetics of human 3 -phosphoadenosine 5 -phosphosulfate synthetase 1
(PAPSSl): gene resequencing, sequence variation, and functional genomics.
Biochem Pharmacol 65:1787-1796.
Yanai, H., Javitt, N. B., Higashi, Y., Euda, H., Strott, C. A. (2004). Expression of
cholesterol sulfotransferase (SULT2Blb) in human platelets. Circulation 109:92-
96 .
Zheng, W., Xie, D., Cerhan, J. R., Sellers, T. A., Wen, W., Eolsom, A. R. (2001).
Sulfotransferase lAl polymorphism, endogenous estrogen exposure, well-done
meat intake, and breast cancer risk.
Cancer Epidemiol Biomark Prev
10:89-94.
Zhu, X., Veronese, M. E., Bernard, C. C , Sansom, L. N., McM anus, M. E. (1993).
Identification of two human brain sulfotransferase cDNAs.Biochem Biophys Res
Commun 195:120-127.
Zou, J., Pentney, R., Roth, J. A. (1990). Immunohistochemical detection of phenol
sulfotransferase-containing neurons in human brain.
J Neurochem
55:1154-1158.
-
8/10/2019 sulfonacion en farmacologa y toxicologa 2 004.pdf
22/22